BioMarin Pharmaceutical Inc.
BMRN US
BMRN USBioMarin Pharmaceutical Inc.
United States Composite80.76
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
- Business
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Company News
Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
Wells Fargo Remains a Buy on BioMarin Pharmaceutical (BMRN)
Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
BioMarin Pharmaceutical (BMRN) Gets a Buy from TD Cowen